WuXi AppTec stock at EUR 23.68, volume 45.2 percent below average
Published on 10/12/2026 at 14:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- WuXi AppTec stock was at EUR 23.68 at Lang & Schwarz on October 12, 2026.
- Trading volume was 45.2 percent below the average, with 29,788,754 shares traded against 54,388,671.
- Second-quarter 2026 revenue reached CNY 16.46 billion and net income was CNY 6.43 billion.
- WuXi AppTec is scheduled to report its quarter ended September 30, 2026 on October 27, 2026.
- Simply Wall St reduced its fair value target from CNY 230.00 to CNY 224.81 on October 7, 2026.
WuXi AppTec (ISIN CNE100003F19) was trading at EUR 23.68 at Lang & Schwarz on October 12, 2026 at 2:20 p.m. CEST, while volume stood 45.2 percent below its average at 29,788,754 shares versus 54,388,671. The next scheduled results date gives the market a clear calendar marker.
Results date sets the next marker
finanzen.ch reported on October 12, 2026 that WuXi AppTec is expected to publish results for the quarter ended September 30, 2026 on October 27, 2026. The same report cites consensus revenue of HKD 18.10 billion, up 37.55 percent from HKD 13.16 billion in the year-earlier quarter, based on two analyst estimates.
The latest reported quarter ended June 30, 2026. TickerLandia lists revenue of CNY 16.46 billion, net income of CNY 6.43 billion and a 39.1 percent net margin for that period. Revenue exceeded the cited estimate of CNY 12.97 billion, while earnings per share reached CNY 2.18 against an estimate of CNY 1.57.
Valuation remains tied to targets
On October 7, 2026, Simply Wall St said the fair value target had been reduced from CNY 230.00 to CNY 224.81. The change followed revised assumptions for discount rates, revenue growth, profit margins and future price-to-earnings multiples.
WuXi AppTec describes its business as an integrated contract research, development and manufacturing organization serving pharmaceutical and life sciences companies across more than 30 countries, according to its investor relations page. The combination of second-quarter operating figures and the October 27 reporting date makes execution against the next consensus estimate the main measurable checkpoint.
Peer figures below are dated October 9, 2026.
Comparison with peers
WuXi AppTec: , P/E 21.22, market capitalization CNY 390.4 billion
Pfizer (NYSE, USD): plus 1.65 percent, P/E 37.37, market capitalization USD 161.2 billion
Thermo Fisher Scientific (NYSE, USD): plus 0.93 percent, P/E 35.40, market capitalization USD 243.3 billion
Price and trading position
WuXi AppTec's Shanghai-listed shares were last at CNY 157.85 on October 12, 2026 at 9:00 a.m. CEST, with a 52-week range of CNY 87.09 to CNY 173.60. The price stood 9.10 percent below the 52-week high, while the company's market capitalization was CNY 390.4 billion.
At Lang & Schwarz, the stock was trading at EUR 23.68 on October 12, 2026 at 2:20 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of WuXi AppTec stock.
WuXi AppTec stock facts
- Company: WuXi AppTec Co., Ltd.
- ISIN: CNE100003F19
- Ticker: 603259.SH, 2359.HK
- Primary exchange: Shanghai Stock Exchange and Hong Kong Stock Exchange
- Price Lang & Schwarz as of October 12, 2026, 2:20 p.m. CEST: EUR 23.68
- Market capitalization: CNY 390.4 billion (as of October 12, 2026)
- 52-week range: CNY 87.09-173.60 (as of October 12, 2026)
- Sector / Industry: Healthcare / contract research, development and manufacturing
- Next earnings date: October 27, 2026
Market context: Market report Shanghai Composite.
